Optical monitoring of glucose demand and vascular delivery in a preclinical murine model

Targeted therapies such as PI3K inhibition can affect tumor vasculature, and hence delivery of imaging agents like FDG, while independently modifying intrinsic glucose demand. Therefore, it is important to identify whether perceived changes in glucose uptake are caused by vascular or true metabolic changes. This study sought to develop an optical strategy for quantifying tissue glucose uptake free of cross-talk from tracer delivery effects. Glucose uptake kinetics were measured using a fluorescent D-glucose derivative 2-(N-(7-Nitrobenz-2-oxa-1,3-diazol-4-yl)Amino)-2-deoxy-Dglucose (2-NBDG), and 2-(N-(7-Nitrobenz-2-oxa-1,3-diazol-4-yl)Amino)-2-deoxy-L-glucose (2-NBDLG) was used as a control to report on non-specific uptake. Vascular oxygenation (SO2) was calculated from wavelength-dependent hemoglobin absorption. We have previously shown that the rate of 2-NBDG delivery in vivo profoundly affects perceived demand. In this study, we investigated the potential of the ratio of 2-NBDG uptake to the rate of delivery (2-NBDG60/RD) to report on 2-NBDG demand in vivo free from confounding delivery effects. In normal murine tissue, we show that 2-NBDG60/RD can distinguish specific uptake from non-specific cell membrane binding, whereas fluorescence intensity alone cannot. The ratio 2-NBDG60/RD also correlates with blood glucose more strongly than 2-NBDG60 does in normal murine tissue. Additionally, 2-NBDG60/RD can distinguish normal murine tissue from a murine metastatic tumor across a range of SO2 values. The results presented here indicate that the ratio of 2-NBDG uptake to the rate of 2-NBDG delivery (2- NBDG60/RD) is superior to 2-NBDG intensity alone for quantifying changes in glucose demand.

[1]  C. Schnell,et al.  Effects of the dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 on the tumor vasculature: implications for clinical imaging. , 2008, Cancer research.

[2]  D. Mankoff,et al.  Tumor Metabolism and Blood Flow as Assessed by Positron Emission Tomography Varies by Tumor Subtype in Locally Advanced Breast Cancer , 2010, Clinical Cancer Research.

[3]  F. Castell,et al.  Quantitative techniques in 18FDG PET scanning in oncology , 2008, British Journal of Cancer.

[4]  R. Wahl,et al.  FDG metabolism and uptake versus blood flow in women with untreated primary breast cancers , 2003, European Journal of Nuclear Medicine and Molecular Imaging.

[5]  P. Okunieff,et al.  Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. , 1989, Cancer research.

[6]  Chi V Dang,et al.  Links between metabolism and cancer. , 2012, Genes & development.

[7]  D. Millhorn,et al.  Bcl-2/adenovirus E1B 19 kDa interacting protein-3 knockdown enables growth of breast cancer metastases in the lung, liver, and bone. , 2005, Cancer research.

[8]  Van der Leij,et al.  Optimizing treatment of low risk breast cancer patients , 2017 .

[9]  P. Vaupel,et al.  Pathophysiological and vascular characteristics of tumours and their importance for hyperthermia: Heterogeneity is the key issue , 2010, International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group.

[10]  Lei Xu,et al.  Normalization of the vasculature for treatment of cancer and other diseases. , 2011, Physiological reviews.

[11]  K. Oh,et al.  A novel fluorescent derivative of glucose applicable to the assessment of glucose uptake activity of Escherichia coli. , 1996, Biochimica et biophysica acta.

[12]  Katsuya Yamada,et al.  Synthesis of 2-NBDLG, a fluorescent derivative of l-glucosamine; the antipode of d-glucose tracer 2-NBDG , 2008 .

[13]  Andreas Meisel,et al.  Sugar for the brain: the role of glucose in physiological and pathological brain function , 2013, Trends in Neurosciences.

[14]  Nizar Mullani,et al.  Uptake of a Fluorescent Deoxyglucose Analog (2-NBDG) in Tumor Cells , 2005, Molecular Imaging and Biology.

[15]  L. Strauss,et al.  Tumor Aggressiveness and Patient Outcome in Cancer of the Pancreas Assessed by Dynamic 18F-FDG PET/CT , 2013, The Journal of Nuclear Medicine.

[16]  Siqing Shan,et al.  In vivo optical molecular imaging and analysis in mice using dorsal window chamber models applied to hypoxia, vasculature and fluorescent reporters , 2011, Nature Protocols.

[17]  N. Denko,et al.  Hypoxia, HIF1 and glucose metabolism in the solid tumour , 2008, Nature Reviews Cancer.

[18]  Hideaki Matsuoka,et al.  A real-time method of imaging glucose uptake in single, living mammalian cells , 2007, Nature Protocols.

[19]  M. Roizen,et al.  Hallmarks of Cancer: The Next Generation , 2012 .

[20]  Johannes A Langendijk,et al.  PET Imaging of Tumor Hypoxia Using 18F-Fluoroazomycin Arabinoside in Stage III–IV Non–Small Cell Lung Cancer Patients , 2013, The Journal of Nuclear Medicine.

[21]  M. Dewhirst,et al.  Optical imaging of tumor hypoxia dynamics. , 2010, Journal of biomedical optics.

[22]  Timothy J. Muldoon,et al.  Molecular imaging of glucose uptake in oral neoplasia following topical application of fluorescently labeled deoxy‐glucose , 2009, International journal of cancer.

[23]  Julie H. Ostrander,et al.  Uptake of 2-NBDG as a method to monitor therapy response in breast cancer cell lines , 2011, Breast Cancer Research and Treatment.

[24]  M. Dewhirst,et al.  Hyperspectral imaging of hemoglobin saturation in tumor microvasculature and tumor hypoxia development. , 2005, Journal of biomedical optics.

[25]  Amy E. Frees,et al.  Delivery Rate Affects Uptake of a Fluorescent Glucose Analog in Murine Metastatic Breast Cancer , 2013, PloS one.

[26]  Umar Mahmood,et al.  Evaluation and clinically relevant applications of a fluorescent imaging analog to fluorodeoxyglucose positron emission tomography. , 2009, Journal of biomedical optics.

[27]  D. Mankoff,et al.  Blood Flow-Metabolism Mismatch: Good for the Tumor, Bad for the Patient , 2009, Clinical Cancer Research.